**Background**
Angiogenesis, the process of forming new blood vessels from pre-existing ones, is a critical requirement for tumor growth and metastasis. The vascular endothelial growth factor (VEGF) pathway, particularly the activation of VEGFR2 (KDR), plays a pivotal role in stimulating the proliferation and migration of endothelial cells to support the nutrient and oxygen demands of expanding tumors. Consequently, targeting the VEGFR2 tyrosine kinase has become a primary strategy in the development of anti-angiogenic therapies for various malignancies. Inhibiting this pathway can starve tumors of their blood supply and potentially sensitize them to other chemotherapeutic agents. In this context, we will introduce a potent inhibitor of VEGFR2 – Vatalanib.
**Definition**
Vatalanib (also known as PTK787, ZK-222584, or CGP-79787) is an inhibitor of VEGFR2/KDR with an IC50 value of 37 nM.
**In Vitro and In Vivo Studies**
According to the Vatalanib description, this compound also inhibits Flk, c-Kit, and PDGFRβ with IC50 values of 270 nM, 730 nM, and 580 nM, respectively. Vatalanib in vitro studies demonstrate that it inhibits thymidine incorporation induced by VEGF in HUVECs with an IC50 of 7.1 nM and dose-dependently suppresses the survival and migration of endothelial cells without exhibiting cytotoxic effects on cells that do not express VEGF receptors. Furthermore, Vatalanib Cancer research has shown that it significantly inhibits the growth of hepatocellular carcinoma cells and enhances IFN/5-FU induced apoptosis by increasing Bax protein levels while reducing Bcl-xL and Bcl-2. Cellular effect data indicates that Vatalanib exhibits cytotoxicity against human A549 and HT-29 cells with IC50 values of 21.16 μM and 22.11 μM, respectively, after 72 hours of treatment. Additionally, it inhibits VEGFR2 phosphorylation in CHO cells (IC50 = 0.016 μM) and HEK293 cells (IC50 = 0.021 μM).
Vatalanib in vivo studies indicate that once-daily oral dosing (25-100 mg/kg) induces dose-dependent inhibition of the angiogenic response to VEGF and PDGF in both growth factor implant and tumor cell-driven angiogenesis models. In the same dose range, Vatalanib inhibits the growth and metastases of several human carcinomas in nude mice without significant effects on bone marrow leukocytes or circulating blood cells. In conclusion, Vatalanib is a potent multi-target tyrosine kinase inhibitor that effectively suppresses angiogenesis and tumor progression.
Keywords
Vatalanib, 212141-54-3, PTK787, ZK-222584, CGP-79787, PTK 787, PTK-787, ZK222584, ZK 222584, CGP79787, CGP 79787, VEGFR, Vascular endothelial growth factor receptor
References
[1] Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8
[2] Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.
[3] Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308.